Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Norwegian Cruise Line Holdings Ltd — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Norwegian Cruise Line Holdings Ltd trades at $14.92 (market cap $6.83B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Norwegian Cruise Line Holdings Ltd for 69 Days on average.
| MRVI | NCLH | |
|---|---|---|
Market Cap | $977.37M | $6.83B |
Volume | 2,742,564 | 16,506,314 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $25.02 |
52-Week Low | $2.83 | $14.12 |
Typical Hold Time | 0 Days | 69 Days |
Enterprise Value | $1.08B | $21.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NCLH trades at $15.32, down 0.2% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Revenue grew to $9.83B in 2025, with a net income margin of 4.3%. Valuation ratios appear attractive with a P/E of 9.28 and P/S of 0.74. Recent news highlights pricing strategies to boost advance bookings and a $950M senior notes offering.
The outlook is mixed: strong earnings beats and analyst buy consensus (51.35%) support upside to the $20.86 price target, but high debt levels and yield pressure pose risks. Investors should weigh solid fundamentals against industry headwinds and financial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
